Susquehanna International Group LLP Buys New Holdings in Pfenex Inc (PFNX)
Susquehanna International Group LLP bought a new stake in shares of Pfenex Inc (NYSEMKT:PFNX) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 67,906 shares of the biotechnology company’s stock, valued at approximately $272,000. Susquehanna International Group LLP owned approximately 0.29% of Pfenex as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of PFNX. Russell Investments Group Ltd. grew its holdings in Pfenex by 221.0% during the 1st quarter. Russell Investments Group Ltd. now owns 32,186 shares of the biotechnology company’s stock valued at $187,000 after buying an additional 22,160 shares in the last quarter. LMR Partners LLP purchased a new position in shares of Pfenex during the second quarter worth about $252,000. Goldman Sachs Group Inc. grew its holdings in shares of Pfenex by 126.7% during the first quarter. Goldman Sachs Group Inc. now owns 56,020 shares of the biotechnology company’s stock worth $325,000 after purchasing an additional 31,308 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of Pfenex by 2,567.5% during the second quarter. Legal & General Group Plc now owns 110,249 shares of the biotechnology company’s stock worth $442,000 after purchasing an additional 106,116 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Pfenex by 2,736.1% during the first quarter. Bank of America Corp DE now owns 80,289 shares of the biotechnology company’s stock worth $467,000 after purchasing an additional 77,458 shares in the last quarter.
Several research analysts have recently commented on PFNX shares. William Blair reissued an “ourperform” rating on shares of Pfenex in a report on Friday, September 8th. Zacks Investment Research raised Pfenex from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a report on Wednesday, July 19th. Finally, ValuEngine lowered Pfenex from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.
Shares of Pfenex Inc (NYSEMKT:PFNX) opened at 2.63 on Tuesday. Pfenex Inc has a 52 week low of $2.63 and a 52 week high of $11.35. The firm has a 50-day moving average price of $3.22 and a 200 day moving average price of $4.14. The stock has a market cap of $61.88 million, a price-to-earnings ratio of 42.42 and a beta of 4.65.
Pfenex (NYSEMKT:PFNX) last issued its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.06). The firm had revenue of $3.03 million for the quarter, compared to the consensus estimate of $3.10 million. Pfenex had a negative net margin of 406.87% and a negative return on equity of 75.61%. The company’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period last year, the firm earned ($0.43) earnings per share. On average, analysts forecast that Pfenex Inc will post ($2.09) EPS for the current fiscal year.
Pfenex Company Profile
Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).
Receive News & Ratings for Pfenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.